Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

G Jones, A Sebba, J Gu, M B Lowenstein, A Calvo, J J Gomez-Reino, D A Siri, M Tomšič, E Alecock, T Woodworth, M C Genovese

ABSTRACT

Background: The anti-interleukin (IL) 6 receptor antibody tocilizumab inhibits signalling of IL6, a key cytokine in rheumatoid arthritis (RA) pathogenesis.

Objective: To evaluate through the AMBITION study the efficacy and safety of tocilizumab monotherapy versus methotrexate in patients with active RA for whom previous treatment with methotrexate/biological agents had not failed.

Methods: This 24-week, double-blind, double-dummy, parallel-group study, randomised 673 patients to either tocilizumab 8 mg/kg every 4 weeks, or methotrexate, starting at 7.5 mg/week and titrated to 20 mg/week within 8 weeks, or placebo for 8 weeks followed by tocilizumab 8 mg/kg. The primary end point was the proportion of patients achieving American College of Rheumatology (ACR) 20 response at week 24.

Results: The intention-to-treat analysis demonstrated that tocilizumab was better than methotrexate treatment with a higher ACR20 response (69.9 vs 52.5%; p<0.001), and 28-joint Disease Activity Score (DAS28) <2.6 rate (33.6 vs 12.1%) at week 24. Mean high-sensitivity C-reactive protein was within the normal range from week 12 with tocilizumab, whereas levels remained elevated with methotrexate. The incidence of serious adverse events with tocilizumab was 3.8% versus 2.8% with methotrexate (p = 0.50), and of serious infections, 1.4% versus 0.7%, respectively. There was a higher incidence of reversible grade 3 neutropenia (3.1% vs 0.4%) and increased total cholesterol >240 mg/dl (13.2% vs 4.0%), and a lower incidence of alanine aminotransferase elevations >3×–<5× upper limit of normal (1.0% vs 2.5%), respectively.

Conclusion: Tocilizumab monotherapy is better than methotrexate monotherapy, with rapid improvement in RA signs and symptoms, and a favourable benefit–risk, in patients for whom treatment with methotrexate or biological agents had not previously failed.

Trial registration number: NCT00109408

Rheumatoid arthritis (RA) is a systemic inflammatory disease characterised by joint pain, stiffness and swelling due to synovial inflammation, as well as fatigue and limitations in physical function, and increased morbidity and mortality.1

Interleukin 6 (IL6) is a pleiotropic proinflammatory cytokine produced by multiple cell types and involved in diverse physiological and pathological processes.3 Raised serum and synovial fluid IL6 levels correlate with disease activity in patients with RA; thus, inhibition of IL6 represents a novel therapeutic approach to treatment.4

Tocilizumab is a humanised anti-IL6 receptor antibody that inhibits both soluble and membrane-expressed IL6 receptors (IL6R) limiting multiple IL6 proinflammatory activities through inhibition of the gp130 pathway.6,7 Tocilizumab has demonstrated efficacy in moderate to severe active RA with inadequate clinical response to disease-modifying antirheumatic drugs (DMARDs) or to tumour necrosis factor (TNF) inhibitors.6–15 Moreover, in a phase 3 study in Japan, more patients receiving tocilizumab 8 mg/kg monotherapy showed reduced radiographic progression than those receiving DMARDs.16 However, tocilizumab has not been studied in patients for whom DMARDs have not previously failed.

Methotrexate remains the most commonly used DMARD and is the recommended standard against which new DMARDs should be evaluated.14–16 To date, there is limited evidence that monotherapy with other treatments is better than methotrexate, as neither etanercept nor adalimumab monotherapy were statistically better than methotrexate in standard clinical efficacy parameters at 24 weeks in the ERA, TEMPO, and PREMIER trials.17–19 The objective of the AMBITION (Actemra versus Methotrexate double-Blind Investigative Trial In mOnotherapy) study was to compare the efficacy and safety of tocilizumab monotherapy with that of methotrexate monotherapy in patients with active RA for whom treatment with methotrexate or biological agents had not previously failed.

PATIENTS AND METHODS

Patients

Patients were ≥18 years, with moderate to severe RA for ≥3 months. Active RA was defined by the presence of ≥6 swollen joints (SJC) from a total of 66, ≥8 tender joints (TJC) from a total of 68, and a C-reactive protein (CRP) level ≥1 mg/dl or erythrocyte sedimentation rate (ESR) ≥28 mm/h. Oral glucocorticoids (up to 10 mg/day prednisone or equivalent) and non-steroidal anti-inflammatory drugs were permitted if the dose was stable for ≥6 weeks. Patients were excluded if they had clinically unstable concurrent illnesses (and screened according to local standards and also excluded if they had active or untreated latent tuberculosis), had been unsuccessfully treated with an anti-TNFα agent, had received methotrexate in the 6 months preceding randomisation or discontinued previous methotrexate treatment because of clinically important adverse effects or lack of efficacy. Patients who had temporarily discontinued
methotrexate treatment owing to side effects or wanted to become pregnant and those who discontinued anti-TNFα treatment for reasons other than efficacy (eg, treatment cost, side effects) could be included in the study.

Study protocol
Patients were randomised in a double-blind, double-dummy fashion to either tocilizumab 8 mg/kg intravenously every 4 weeks, or to methotrexate oral capsules, weekly (escalating dose regimen: initial dose 7.5 mg, increasing to 15 mg at week 4 and to 20 mg at week 8) together with folate (>5 mg/week). Methotrexate dose reduction to 10 mg weekly was permitted for safety reasons.

Patients were assessed for efficacy and safety using a dual assessor approach to ensure blinded evaluation for efficacy; a trained joint assessor, with no access to patient data, performed each SJC and TJC.

To enable sensitivity testing for the non-inferiority claim, patients in the USA, Canada, and Israel were randomised (1:1:1) to the previously described two arms and an additional placebo arm as part of a substudy (fig 1). In the placebo arm patients received methotrexate placebo and tocilizumab placebo for 8 weeks (two infusions); from week 8 placebo infusion was replaced by tocilizumab 8 mg/kg infusion for the remaining 16 weeks of the study. Patients taking part in the placebo-controlled substudy who experienced 20% worsening from baseline in the SJC and TJC before week 8 could receive rescue treatment with tocilizumab 8 mg/kg for the remaining 16 weeks of double-blind treatment; ITT, intention to treat; PP, per-protocol.

Study end points
The primary end point was the proportion of patients with an ACR20 response at week 24. Secondary end points included the proportion of patients with ACR50/70 responses at week 24, and the time to onset of ACR20/50/70 responses. Changes from baseline at week 24 in 28-joint count Disease Activity Score (DAS28; using ESR) were also evaluated. The proportion of patients in clinical remission (with DAS28 <2.6), with low disease activity (DAS28 ≤3.2) and with EULAR good/moderate responses at week 24 were assessed.

Improvement in physical function was assessed by change from baseline at week 24 in the Health Assessment Questionnaire-Disability Index (HAQ-DI).

Safety assessments
Patients were monitored for adverse events (AEs), serious AEs, infections, withdrawals due to AEs, deaths and clinically significant changes in vital signs and laboratory tests.

Statistical methodology
The primary analysis group for the assessment of both efficacy and safety consisted of all patients randomised to either tocilizumab or methotrexate; patients initially randomised to placebo were assessed in subanalyses. The intention-to-treat (ITT) population included all randomised patients who received at least one infusion of the study treatment; depending on the purpose of analysis, ITT patients initially randomised to placebo were excluded. The per-protocol population (PP) included all patients in the ITT population who received more than two-thirds of the study treatments and did not change concomitant

Figure 1  Study enrolment, randomisation and study completion. *Includes one patient who did not complete 24 weeks of treatment and therefore should have been counted as having withdrawn prematurely; **includes one patient who missed the first dose of intravenous study drug, but received 24 weeks of the oral study drug and therefore should have been considered a completer; ***only patients enrolled in the placebo controlled substudy could receive rescue treatment with tocilizumab 8 mg/kg within the first 8 weeks of double-blind treatment; ITT, intention to treat; PP, per-protocol.
Extended report

Table 1 Patients demographics and baseline characteristics (PP and ITT populations)

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Tocilizumab 8 mg/kg</th>
<th>Methotrexate</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PP (n = 265)</td>
<td>ITT (n = 286)</td>
</tr>
<tr>
<td>Age (years), mean (SD)</td>
<td>51.1 (13.1)</td>
<td>50.7 (13.1)</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>219 (83)</td>
<td>236 (83)</td>
</tr>
<tr>
<td>Duration of disease, years</td>
<td>6.4 (7.7)</td>
<td>6.4 (7.9)</td>
</tr>
<tr>
<td>Median (min–max)</td>
<td>3.2 (0.1–44.7)</td>
<td>3.1 (0.1–44.7)</td>
</tr>
<tr>
<td>Disease duration &lt;2 years, n (%)*</td>
<td>117 (41)</td>
<td>125 (44)</td>
</tr>
<tr>
<td>Previous DMARDs/anti-TNF blockers (n), mean (SD)</td>
<td>1.2 (1.3)</td>
<td>1.2 (1.3)</td>
</tr>
<tr>
<td>Methotrexate naïve, n (%)</td>
<td>176 (66)</td>
<td>191 (67)</td>
</tr>
<tr>
<td>Methotrexate use, n (%)</td>
<td>128 (48)</td>
<td>137 (48)</td>
</tr>
<tr>
<td>Haemoglobin value &lt;LLN, n (%)</td>
<td>101 (38)</td>
<td>115 (44)</td>
</tr>
<tr>
<td>TJC, mean (SD)</td>
<td>32.2 (14.7)</td>
<td>31.8 (14.8)</td>
</tr>
<tr>
<td>SJC, mean (SD)</td>
<td>19.3 (11.2)</td>
<td>19.1 (11.0)</td>
</tr>
<tr>
<td>CRP (mg/dl), mean (SD)</td>
<td>2.9 (3.2)</td>
<td>3.0 (3.3)</td>
</tr>
<tr>
<td>ESR (mm/h), mean (SD)</td>
<td>49.9 (27.6)</td>
<td>49.9 (27.9)</td>
</tr>
<tr>
<td>HAQ-DI, mean (SD)</td>
<td>1.6 (0.7)</td>
<td>1.6 (0.7)</td>
</tr>
<tr>
<td>Pain VAS 100 mm, mean (SD)</td>
<td>59.2 (22.5)</td>
<td>58.7 (22.9)</td>
</tr>
<tr>
<td>Patient VAS 100 mm, mean (SD)</td>
<td>64.0 (21.5)</td>
<td>63.9 (21.9)</td>
</tr>
<tr>
<td>Physician VAS 100 mm, mean (SD)</td>
<td>63.2 (15.7)</td>
<td>63.0 (16.1)</td>
</tr>
</tbody>
</table>

*Safety population (tocilizumab 8 mg/kg, n = 288; methotrexate, n = 284).

Corticosteroids or non-steroidal anti-inflammatory drugs. The safety population included all randomised patients who received ≥1 infusion and ≥1 post-randomisation safety assessment.

The primary efficacy analysis was a non-inferiority comparison of tocilizumab with methotrexate using the PP population. The null hypothesis was that the proportion of patients with an ACR20 response in the tocilizumab treatment arm would be more than 12 percentage points lower than the proportion of patients in the methotrexate arm at week 24. If non-inferiority was met, superiority of tocilizumab was to be tested using the primary analysis ITT population. ACR20 response rates were analysed using extended Mantel–Haenszel statistics, with adjustment stratification applied at randomisation (site and disease duration). A sample size of 275 patients per arm would provide at least 90% power to test the null hypothesis.

To support the primary endpoint result, the same analysis (using the ITT population) was performed at week 8 between the tocilizumab and placebo groups. A comparison of 100 placebo patients with 275 tocilizumab patients would provide a >90% power to demonstrate tocilizumab superiority to placebo at week 8.

For secondary end points, no non-inferiority limits were predefined; however, superiority was achieved if the lower limit of the 95% confidence interval (95% CI) for treatment difference between tocilizumab and methotrexate was higher than 0 in the ITT population analysis. Changes from baseline in DAS28, CRP, haemoglobin and HAQ-DI at week 24 were compared between treatment groups using an analysis of covariance model. The proportion of patients with a DAS28 score <2.6 and EULAR response at week 24 were compared between treatment groups using logistic regression.

RESULTS
Patient randomisation and baseline demographics
A total of 673 patients were randomised into the study (fig 1). Most patients completed 24 weeks’ treatment: 268 (93%) patients in the tocilizumab group and 262 (92%) patients in the methotrexate group. General demographic and baseline characteristics were well balanced (table 1). The majority of the patients were methotrexate-naive (~66% per arm) with a mean disease duration of 5 years; the mean number of previous DMARDs/anti-TNFs was 0.5 and only 40% had previously been treated with oral steroids. The mean weekly methotrexate dose over 24 weeks was 15.5 mg, with 73.5% of patients attaining 20 mg weekly at week 8.

Clinical efficacy
Improvement in signs and symptoms
After establishing non-inferiority in the PP population (ACR20 at week 24: 70.6% for tocilizumab versus 52.1% for methotrexate; weighted difference 0.21 (95% CI 0.13 to 0.29)), tocilizumab was confirmed as superior to methotrexate (ITT), with a weighted difference for ACR20 response at week 24 of 0.19 (95% CI 0.11 to 0.27, p<0.001; fig 2A). Furthermore, compared with the placebo control arm, tocilizumab was also superior at week 8 (ACR20: 55.6 vs 13.1%, ITT) with a weighted difference of 0.43 (95% CI 0.34 to 0.52). The superiority of tocilizumab was also present in an exploratory analysis of MTX-naive patients (ITT; fig 2B).

The proportion of ACR50 (44%) and ACR70 (28%) responders (ITT; fig 2A) at week 24 was also statistically superior for tocilizumab compared with methotrexate (weighted difference between treatments: 0.12 for ACR50 (95% CI 0.04 to 0.20; p = 0.002); and 0.14 for ACR70 (95% CI 0.07 to 0.22; p<0.001)). The ACR20 response rate with tocilizumab was statistically better than that of methotrexate as early as week 2 (ITT: 24.1 vs 10.2%), with differences between the groups increasing over time. Compared with methotrexate, ACR50 and ACR70 responses were consistently observed in more tocilizumab-treated patients from week 4 and week 8 onwards (fig 2C).
Mean changes from baseline at week 24 in the ACR core parameters were consistently greater for tocilizumab than for methotrexate (table 2). A greater improvement in physical function was also reflected by the higher mean changes from baseline in HAQ-DI with tocilizumab.

Improvement in DAS28 at week 24 (ITT) was greater in the tocilizumab group than in the methotrexate group (adjusted mean change from baseline: $-3.31$ vs $-2.05$), and the proportion of patients in remission (DAS28 $<2.6$) at week 24 (ITT) was higher with tocilizumab than with methotrexate (fig 2D). By week 24, tocilizumab patients were five times more likely to achieve DAS28 remission (odds ratio vs methotrexate: $5.83$, 95% CI 3.27 to 10.40), and approximately four times more likely to achieve at least a moderate EULAR response (odds ratio vs methotrexate: $4.24$, 95% CI 2.92 to 6.14; fig 2D).

Notably, mean CRP levels were within the normal range as early as week 2 with tocilizumab, with persistently normal levels from weeks 12 to 24 in more than 90% of patients (fig 2E, table 2). Furthermore, adjusted mean haemoglobin levels increased by $1.19$ g/dl from baseline in the tocilizumab group, and $0.10$ g/dl in the methotrexate group (ITT) by week 24. Improvement in haemoglobin levels was seen as early as week 2 (safety population; fig 2F) with normalisation of mean haemoglobin by week 6 in tocilizumab-treated patients with haemoglobin less than the lower limit of normal at baseline, an effect maintained through week 24 (13.4 g/dl; PP), not seen with methotrexate (12.3 g/dl).

**Figure 2**  Improvement in signs and symptoms of disease. (A) Proportion of patients achieving ACR20, ACR50 and ACR70 responses at week 24 (ITT population). Results demonstrate that treatment with tocilizumab is significantly better than treatment with methotrexate (*p < 0.001; **p = 0.002; ***p < 0.001). (B) Proportion of methotrexate-naïve patients achieving ACR20, ACR50 and ACR70 responses at week 24 (ITT population); *Weighted difference between groups 0.15 (95% CI 0.05 to 0.25), p = 0.004; **Weighted difference between groups 0.14 (95% CI 0.03 to 0.24), p = 0.01; ***Weighted difference between groups 0.15 (95% CI 0.04 to 0.25), p = 0.005. (C) Time course for achievement of ACR20, ACR50 and ACR70 responses during 24 weeks of treatment with tocilizumab or methotrexate (ITT population). (D) Proportion of patients in clinical remission (DAS28 $<2.6$) and proportion of patients with good/moderate EULAR response at week 24 (ITT population). (E) CRP levels at each post-baseline visit during the 24-week study (ITT population); (F) Haemoglobin levels at each post-baseline visit during the 24-week study (safety population). CRP, C-reactive protein; DAS28, 28-joint Disease Activity Score; ITT, intention to treat; LLN, lower limit of normal; ULN, upper limit of normal.
 the overall incidence of adverse events (AEs) was similar in both groups (79.9% tocilizumab vs 77.5% methotrexate; \( p = 0.484 \)), with fewer than 7% of patients experiencing severe AEs. The most common AEs during the study were infections (tocilizumab, 34.4% vs methotrexate, 37.3%; table 4). Infusion rates per patient year were similar (tocilizumab, 1.06 vs methotrexate, 1.09). Skin and subcutaneous infections were reported in 10.7% of patients with tocilizumab and 1.8% with methotrexate (\( p = 0.016 \)). The second most common AEs were gastrointestinal disorders, occurring with similar frequency in both groups. Five (1.8%) patients in the methotrexate group and one (0.3%) patient in the tocilizumab group were withdrawn from the study owing to gastrointestinal AEs.

Infusion reactions (any AE occurring during, or within 24 h after infusion) occurred in 5.6% of patients with tocilizumab and 1.8% with methotrexate (\( p = 0.016 \)). The majority occurred during the first two infusions (tocilizumab: 10/16; methotrexate: 5/6); no serious infusion reactions were reported.

Four patients died during the study: one in the methotrexate group (lung cancer), and three in the tocilizumab group (upper gastrointestinal haemorrhage/perforation (one), myocardial ischaemia (one) and cardiorespiratory arrest in a patient with history of asthma and arrhythmia (one)). The death due to gastrointestinal haemorrhage was considered by the investigator to be remotely related to treatment owing to short exposure to tocilizumab and the patient's medical history (peptic ulcer), although a relationship with treatment could not be excluded. The other three deaths were deemed unrelated to the trial treatment.

More patients had reversible grade 3 neutropenia (<1000–5000 cells/mm\(^3\)) with tocilizumab, 3.1 versus methotrexate, 0.4% (fig 5A). One patient in the placebo/tocilizumab substudy arm discontinued owing to grade 4 neutropenia (<500 cells/mm\(^3\)) and one patient owing to grade 3 neutropenia; both events resolved without sequelae. None of the patients with grade 3 or 4 neutropenia developed an infection or febrile neutropenia within the following month.

Fewer elevations in alanine and aspartate aminotransferase to >3\( \times \) the upper limit of normal (ULN) were seen with tocilizumab than with methotrexate (fig 3B). Three patients in the tocilizumab group compared with two in the methotrexate group discontinued the study treatment owing to aminotransferase elevations. Total bilirubin elevations (mostly indirect component) >ULN and >3\( \times \) ULN were seen in 0.7 and 7.6% of patients in the methotrexate and tocilizumab groups, respectively, with no elevations seen concurrently with aminotransferase elevations. There were no clinical signs or symptoms of hepatitis or hepatic dysfunction.

Total cholesterol and low-density lipoprotein elevations were seen in more patients in the tocilizumab group than in the methotrexate group (fig 5C). No patients in either treatment group had changes in triglycerides from <150 mg/dl to >500 mg/dl. No clinical symptoms or cardiovascular events were reported in these patients.

### DISCUSSION

These results demonstrate the superior efficacy of tocilizumab monotherapy over methotrexate monotherapy regardless of previous methotrexate exposure. Of note, at week 24, almost one-third of tocilizumab-treated patients achieved either DAS remission or an ACR70 in comparison with 12% and 15% of
methotrexate-treated patients, despite approximately two-thirds of patients reaching and maintaining the 20 mg methotrexate dose by week 8. This outcome compares favourably with other trials comparing TNF antagonists with methotrexate using a similar dose titration.\(^{17-19}\) In the ERA trial, which enrolled patients with early RA, clinical endpoint results were similar for etanercept 25 mg twice weekly and methotrexate (dosing similar to this study), with significance for etanercept 50/70 responses were similar for etanercept and methotrexate monotherapy (not significant); however, a greater benefit could have been seen earlier in the treatment course.\(^{17}\) It is unlikely that prior experience with methotrexate significantly influenced results, as a similar proportion of patients in each treatment group (4% in methotrexate group and 3% in tocilizumab group) discontinued owing to AEs, and the reasons for discontinuation related to safety and refusal were comparable overall. To investigate this further, a post hoc analysis was conducted comparing pre-study methotrexate-naïve (\(\leq 66\%\)) patients. Whereas patients exposed to methotrexate before AMBITION had longer mean disease duration (9 vs 5 years), received more DMARDs (2.6 vs 2.1), and had higher use of corticosteroids (60% vs 40%), the efficacy results were similar. Specifically, ACR20/50/70 for tocilizumab-treated patients was 73%/42%/30% (methotrexate-exposed) versus 69%/45%/27% (methotrexate-naïve), and for methotrexate-treated patients were 50%/34%/17% and 54%/33%/14%, respectively.\(^{24-25}\) Combined with radiographic evidence from the SAMURAI study that tocilizumab, compared with DMARDs, inhibits progression of joint damage, the normalisation of CRP with tocilizumab, compared with DMARDs, inhibits progression of joint damage.\(^{24,25}\) It is difficult to compare results across clinical trials owing to It is unlikely that prior experience with methotrexate

| Table 4 Most frequently reported adverse events (in \(\geq5\%\) of patients) |
|-----------------------------------------------|----------------|----------------|----------|
| Adverse events                                      | Tocilizumab 8 mg/kg | Methotrexate 50 mg/kg | p Value |
|Patients with at least one adverse event (total)    | 230 (79.9) | 220 (77.5) | 0.464 |
|Infections (total)                                  | 99 (34.4)  | 106 (37.3) | 0.462 |
| Nasopharyngitis                                     | 20 (6.9)   | 17 (6.0)   | 0.702 |
| Upper respiratory tract infection                   | 21 (7.3)   | 15 (5.3)   |       |
| Gastrointestinal disorders (total)                 | 96 (29.9)  | 89 (31.3)  | 0.008 |
|Nausea                                              | 18 (6.3)   | 34 (12.0)  |       |
|Diarrhoea                                           | 15 (5.2)   | 15 (5.3)   |       |
|Investigations (total)*                             | 48 (16.7)  | 43 (15.1)  | 0.618 |
|Skin and subcutaneous disorders (total)             | 42 (14.6)  | 32 (11.3)  | 0.237 |
|Musculoskeletal and connective tissue disorders (total) | 33 (11.5)  | 32 (11.3)  | 0.943 |
|Nervous system disorders (total)                    | 37 (12.8)  | 18 (6.3)   |       |
|Headache                                            | 21 (7.3)   | 7 (2.5)    |       |
|General disorders and administration site conditions (total) | 21 (7.3) | 24 (8.5) | 0.607 |
|Respiratory, thoracic and mediastinal disorders (total) | 26 (9.0) | 19 (6.7) | 0.299 |
|Vascular disorders (total)                          | 24 (8.3)   | 13 (4.8)   | 0.088 |
|Hypertension                                        | 16 (5.6)   | 6 (2.1)    |       |
|Psychiatric disorders (total)                       | 20 (6.9)   | 11 (3.9)   | 0.105 |
|Injury, poisoning and procedural complications (total) | 14 (4.9) | 15 (5.3) | 0.819 |
|Eye disorders (total)                               | 15 (5.2)   | 9 (3.2)    | 0.224 |

Serious adverse events (in \(\geq 3\) patients)

<table>
<thead>
<tr>
<th>Total number of serious adverse events</th>
<th>12</th>
<th>15</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infections and infestations</td>
<td>4 (1.4)</td>
<td>2 (0.7)</td>
</tr>
<tr>
<td>Sepsis</td>
<td>–</td>
<td>1 (0.4)</td>
</tr>
<tr>
<td>Pneumonia</td>
<td>2 (0.7)</td>
<td>1 (0.4)</td>
</tr>
<tr>
<td>Sinusitis</td>
<td>1 (0.3)</td>
<td>–</td>
</tr>
<tr>
<td>Sialoadenitis</td>
<td>1 (0.3)</td>
<td>–</td>
</tr>
<tr>
<td>Injury, poisoning and procedural complications</td>
<td>1 (0.3)</td>
<td>3 (1.1)</td>
</tr>
<tr>
<td>Neoplasms benign, malignant and unspecified</td>
<td>1 (0.3)</td>
<td>3 (1.1)</td>
</tr>
</tbody>
</table>

Results are shown as n (%).

*Laboratory parameters.
incidence between the groups, serious/severe infections were twice as common with tocilizumab. The nature of serious infections was comparable considering the small numbers, as was the occurrence of herpes zoster. Interestingly, non-serious fungal skin infections occurred only in methotrexate-treated patients.

The other most common AEs were gastrointestinal disorders, with more patients discontinuing in the methotrexate group. Other AEs with an imbalance between the groups, included rash/urticaria, headache, hypertension, which were more common in the tocilizumab group than in the methotrexate group. These events were typically mild, transient and not treatment limiting.
The superior efficacy of tocilizumab in this study provides initial significance of which remains to be determined. Nevertheless, neutropenia associated with IL6R inhibition, the long-term presents a unique safety profile for lipid elevations and reversible neutropenia associated with IL6R inhibition. Modifications of dosing in response to ALT/AST elevations as per-protocol, led to normalisation/improvement in the majority of patients, with more methotrexate patients (four) than tocilizumab patients (one) discontinuing owing to these elevations.

Increases in total cholesterol, low-density lipoprotein and high-density lipoprotein cholesterol were seen in more patients in the tocilizumab group than in the methotrexate group. These changes appeared to be associated with reduction in systemic inflammation, an effect also seen in patients treated with anti-TNF biological agents.13–16 Although cardiovascular events were not seen in patients with these elevations during this study, treatment according to guidelines is recommended to deal with cardiovascular risk, and there remains a need for longer-term follow-up during chronic treatment to determine any implications of this effect.

In conclusion, the AMBITION study demonstrates that the efficacy of tocilizumab monotherapy in patients with relatively early active RA for whom methotrexate has not previously failed, is better than that of methotrexate monotherapy. Compared with methotrexate, tocilizumab monotherapy presents a unique safety profile for lipid elevations and reversible neutropenia associated with IL6R inhibition, the long-term significance of which remains to be determined. Nevertheless, the superior efficacy of tocilizumab in this study provides initial evidence of a benefit-risk that supports its use in patients with active moderate to severe RA.

Acknowledgements: We acknowledge the collaboration and commitment of all investigators and their staff, without whom this study would not have been possible. Editorial support was provided by Marcela Oancea, PhD from Phocus Services, in Basel, Switzerland, supported by F Hoffmann-La Roche Ltd.

Funding: This study was sponsored by F Hoffmann-La Roche Ltd.

Competing interests: GJ has received consulting fees from Merck, Roche, Genzyme, Novartis and Servier and has been paid lecture fees by Merck, Roche, Sanofi-Aventis, Servier, Pfizer and Novartis. AS has received consulting fees from Amgen, Merck, Novartis and Roche, and has been paid lecture fees by Merck, Novartis, Roche, Glaxo Smith Kline and Lilly. AC has received lecture fees from Deutsche Pharma, Farmindustria, Schering Plough and Pfizer, has been paid lecture fees by Bristol-Myers Squibb and Merck, and has received grant support from Bristol-Myers Squibb, Merck and Roche. JG-R has received consulting fees from Roche, Schering Plough, Wyeth and Bristol-Myers Squibb, and has been paid lecture fees by Roche, Wyeth and Bristol-Myers Squibb. AS has received consulting fees from Roche. MT has received consulting fees from Roche and Schering Plough. TW and EA are employees of Roche. MCG has received consulting fees from Roche, Genentech, Biogen-Idec and Bristol-Myers Squibb, has been paid lecture fees by Genentech and Bristol-Myers Squibb and has received grant support from Roche, Genentech, Biogen-Idec, Bristol-Myers Squibb and Pfizer.

Ethics approval: Approved by institutional review boards/ethics committees.

Provenance and peer review: Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Commercial (CC BY-NC) 3.0 license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

REFERENCES


Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

G Jones, A Sebba, J Gu, M B Lowenstein, A Calvo, J J Gomez-Reino, D A Siri, M Tomsic, E Alecock, T Woodworth and M C Genovese

Ann Rheum Dis 2010 69: 88-96 originally published online March 17, 2009
doi: 10.1136/ard.2008.105197

Updated information and services can be found at:
http://ard.bmj.com/content/69/01/88

These include:

References
This article cites 34 articles, 9 of which you can access for free at:
http://ard.bmj.com/content/69/01/88#BIBL

Open Access
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Open access (640)
- Connective tissue disease (4253)
- Degenerative joint disease (4641)
- Immunology (including allergy) (5144)
- Musculoskeletal syndromes (4951)
- Rheumatoid arthritis (3258)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/